O
27.14
-2.05 (-7.02%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Olema Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-1.0
| 分析师共识 | 4.0 |
| 内部交易活动 | -3.5 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -1.00 |
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.32% |
| 机构持股比例 | 98.70% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 60.00 (Citigroup, 121.08%) | 购买 |
| 中 | 45.00 (65.81%) | |
| 低 | 32.00 (JP Morgan, 17.91%) | 购买 |
| 平均值 | 44.67 (64.59%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 29.17 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| UBS | 07 Jan 2026 | 45.00 (65.81%) | 购买 | 27.07 |
| Citigroup | 12 Dec 2025 | 60.00 (121.08%) | 购买 | 33.05 |
| Goldman Sachs | 11 Dec 2025 | 38.00 (40.01%) | 购买 | 31.58 |
| 21 Nov 2025 | 26.00 (-4.20%) | 购买 | 23.17 | |
| HC Wainwright & Co. | 11 Dec 2025 | 45.00 (65.81%) | 购买 | 31.58 |
| 18 Nov 2025 | 36.00 (32.65%) | 购买 | 20.14 | |
| Oppenheimer | 11 Dec 2025 | 48.00 (76.86%) | 购买 | 31.58 |
| 18 Nov 2025 | 45.00 (65.81%) | 购买 | 20.14 | |
| JP Morgan | 18 Nov 2025 | 32.00 (17.91%) | 购买 | 20.14 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HARMON CYRUS | - | 27.75 | -13,489 | -367,579 |
| KOVACS SHANE WILLIAM CHARLES | - | 28.54 | -103,822 | -3,025,596 |
| MYLES DAVID C. | - | 28.48 | -110,000 | -3,120,900 |
| 累积净数量 | -227,311 | |||
| 累积净值 ($) | -6,514,074 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 28.29 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| HARMON CYRUS | 董事 | 20 Jan 2026 | 卖 (-) | 10,000 | 26.72 | 267,200 |
| KOVACS SHANE WILLIAM CHARLES | 职员 | 15 Jan 2026 | 卖 (-) | 100,000 | 29.19 | 2,919,000 |
| MYLES DAVID C. | 职员 | 14 Jan 2026 | 卖 (-) | 50,000 | 28.77 | 1,438,500 |
| MYLES DAVID C. | 职员 | 14 Jan 2026 | 执行期权 | 50,000 | - | - |
| HARMON CYRUS | 董事 | 14 Jan 2026 | 卖 (-) | 3,489 | 28.77 | 100,379 |
| MYLES DAVID C. | 职员 | 13 Jan 2026 | 卖 (-) | 50,000 | 27.89 | 1,394,500 |
| MYLES DAVID C. | 职员 | 13 Jan 2026 | 执行期权 | 50,000 | - | - |
| KOVACS SHANE WILLIAM CHARLES | 职员 | 13 Jan 2026 | 卖 (-) | 3,822 | 27.89 | 106,596 |
| MYLES DAVID C. | 职员 | 12 Jan 2026 | 卖 (-) | 10,000 | 28.79 | 287,900 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合